Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 63c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $245.80 +2.21%
EPS Growth %: -20.4%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
ANAB, ANIX, MNY, More
EPS Growth %: -20.4%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of ($8.25), $0.63 worse than the analyst estimate of ($7.62). Revenue for the quarter came in at $1.05 billion versus the consensus estimate of $1.04 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jazz Pharmaceuticals (JAZZ) PT Raised to $337 at UBS on GEA Approval for Ziihera
- Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance
- Citrini Research acquired by Semianalysis
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
